sector medic suppli devic
 end high note top
messag deliv impress perform organ sale
growth rise high despit challeng yoy comp solid
oper leverag drive ep beat manag expect
year guidanc call ep organ sale
growth given compani current momentum see top half rang
achiev posit one best fundament
stori sector rais pt reiter
buy rate
end high note fourth quarter revenu beat consensu
rose underli basi best organ growth quarter decad
mark compani tenth straight quarter top line gain bring full year
organ growth robust upsid broad-bas medsurg
ortho neurotech spine top street estim within
segment strong quarter mako sharp growth acceler medic
divis better expect spine perform drove bulk beat
top line ep came ahead consensu aid ebita
leverag mark fourth straight quarter featur least margin
expans fail achiev mark accomplish
view impress consid fact came despit
headwind recent drag continu manag commit
anoth leverag year ahead combin forecast
anoth year underli top line gain posit deliv
fourth straight year double-digit ep growth
came despit deliv high level stock
rel underperform past month vs large-cap
med-tech group due larg part investor concern sustain growth
trajectori tuesday result initi outlook help put worri rest
view compani well posit maintain growth
next year strong revenu outlook noth new
howev chang past month compani abil pair
sale growth solid oper leverag even absorb dilut steadi
cadenc tuck-in acquisit help add fuel top line fire two element
place ampl balanc sheet capac avail manag continu pursu
value-cr net debt/ebitda see top shelf fundament
stori within large-cap med-tech stock trade line broader group today
ntm ep vs see ampl room multipl expans
turn back quarter record number mako placement drove upsid
ortho mako system placement rebound sequenti vs modest
declin last quarter robot procedur volum continu ramp overal case
sequenti mako implant rise vs total knee account
 mako case mix includ partial estim
domest knee case perform robot see figur importantli clinic
evid support widespread adopt begin trickl number small
physician-initi studi demonstr use mako result superior acut
outcom includ earlier function recoveri reduc pain shorter length stay
view earli result encourag approach anniversari
launch long-term clinic experi begin matur meantim
note healthi order backlog robot head suggest
momentum exhibit like continu even launch rosa robot
system approach continu page
page analyst certif import disclosur
mako busi continu shine rest ortho busi turn
mix total orthoped sale rose cc came
consensu overal knee sale cc miss consensu expect
 sale growth deceler sequenti albeit
comp tougher meanwhil trauma extrem sale
cc came ahead street forecast growth acceler
sequenti comp tougher back sever new product
launch elsewher hip sale miss consensu growth
cc still repres high water mark year continu enjoy
improv momentum wake recent trident ii acetabular cup launch
compani report guggenheim secur llc estim
compani report guggenheim secur llc estim
meanwhil medic led way medsurg turn solid quarter report
medsurg sale organ consensu upsid
medic drove major beat medic sale organ came
ahead street expect driven resurg perform physio-
control strong contribut core medic meanwhil instrument
organ top consensu driven wast manag micro
power product line elsewher endoscopi sale organ acceler
mediocr perform schedul launch new
camera later quarter novadaq continu deliv strong growth endoscopi
segment pois improv momentum move final
sustain divis post revenu ahead street
elsewher earli return ktwo appear posit total neurotech spine sale
grew organ basi ahead consensu spine chip
strong quarter sale organ growth beat consensu
mark strong improv organ growth seen first nine
month year fair dont believ consensu estim fulli captur
contribut recent close acquisit howev still view step
right direct busi perenni laggard recent
year integr still initi stage today ceo kevin lobo
indic process track ahead schedul thu far express
confid combin busi deliv mid-single-digit growth pro
page analyst certif import disclosur
meanwhil estim neuro organ growth deceler sequenti
revenu miss consensu albeit toughest
comp continu enjoy strong momentum neurovascular
portfolio buoy recent approv surpass flow divert hemorrhag side
new vecta aspir cathet complement trevo stent retriev ischem
top line tight opex control off-set gross margin miss ebita expand
yoy stryker gross margin contract yoy
consensu driven price fx busi mix sg spend increas yoy
sale consensu meanwhil spend grew yoy
sale lower street model collect result
ebita margin yoy in-lin street estim full year
deliv oper margin expans view strong
perform particularli given fact ebita headwind
overal
concern sustain revenu growth subsid see
potenti share re-rat higher model call ep
sale organ compar previou estim
respect long-term believ right mix
end market differenti product expertis sustain top line growth
trajectori next year combin improv execut
margin set compani one best fundament stori large-cap
med-tech view yet year lacklust return share trade
slight premium group ntm ep vs see attract
buy opportun expect stock wednesday back
result think stock re-rat back premium multipl like leg
well beyond week rais price target previous
base multipl previous revis forward ntm ep estim
signific upsid potenti target current level reiter buy
page analyst certif import disclosur
believ diversifi busi model posit sustain revenu growth
high end large-cap group compani seven differ busi
contribut overal revenu one franchis respons
uniqu model insul temporari weak one
segment view allow cast wide net potenti valu creat
acquisit result one consist top line growth stori large-
cap med-tech past year expect continu go forward drive
sustain ep growth potenti faster gain execut around
margin leverag improv deploy balanc sheet capac net
debt/ebitda today product manner believ profil warrant premium
valuat rel peer
share current trade ntm ep estim ntm
ebitda slight premium large-cap med-tech averag ntm ep
ntm ebitda believ superior growth profil peg
top bottom line vs group averag warrant
premium valuat increas price target previous
base multipl previous revis forward ntm ep estim
signific upsid potenti target current level assign stryker buy
downsid risk rate price target includ disappoint ramp mako
total knee applic increas price and/or volum pressur ortho implant
manufactur govern initi contain healthcar cost legal payout
patent product liabil case exceed estim slowdown hospit
capit equip spend could neg impact stryker medsurg growth
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
million usd
compani report guggenheim secur llc estim
page analyst certif import disclosur
